Exo-Linker: Positional Reconfiguration Driving Significant Advances in ADC Stability and Efficacy

Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. However, payload instability, hydrophobicity, and premature cleavage limit their efficacy and safety. This study presents Exo-Linker technology as a novel solution to these issues. By repositioning cleavable peptide linkers like Glu-Val-Cit and Glu-Glu-Val-Cit at the exo-position of the p-aminobenzyl carbamate moiety, Exo-Linkers improve stability, hydrophilicity, and resistance to enzymatic degradation.

Key findings highlight the superior pharmacokinetics, tumor-suppressive efficacy, and enzymatic stability of Exo-Linker ADCs in preclinical models, significantly outperforming traditional Val-Cit-based linkers. Integration with the second-generation AJICAP platform broadens therapeutic windows, ensures precise drug-to-antibody ratio control, and minimizes aggregation. Exo-Linkers establish a new standard for ADC development, overcoming critical limitations of traditional linkers while enabling safer and more effective cancer treatments. This innovative approach redefines the therapeutic landscape, enhances patient outcomes, and broadens the scope of ADC applications.

Read Full Article

Authors: Tomohiro Watanabe*¹, Tomohiro Fujii, Ph.D *², Yutaka Matsuda, Ph.D, Ph.D, MBA,*¹

Advertisement #3 

 

¹ Ajinomoto Bio-Pharma Services, 11040 Roselle Street, San Diego, CA 92121, United States; ² Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.